Royalty Pharma plc Class A Ordinary Shares
Here’s whether Royalty Pharma plc Class A Ordinary Shares (RPRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.07% over 10 days); strong 1-year return of +55.3%; 3-month momentum positive (+26.4%). Concerns: RSI 71 — overbought, elevated pullback risk. Currently 0.0% off its 52-week high. Score: +5/7.
RPRX is in a confirmed uptrend, trading above both its 50-day ($46.36) and 200-day ($39.87) moving averages. With an RSI of 71.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +55.3% compares to +35.1% for SPY (beat the market by 20.2%).